After Regulatory Setbacks, Moderna (MRNA.US) Secures Approval for Its First mRNA Influenza Vaccine—Commercial Prospects Still Await Validation

智通财经2026/08/06 06:41

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

According to Golden Ten Data APP, after previously facing opposition from the U.S. Food and Drug Administration (FDA), Moderna's (MRNA.US) mRNA-based flu vaccine mFLUSIVA has finally been approved for market launch, marking a significant victory for the company.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

After Regulatory Setbacks, Moderna (MRNA.US) Secures Approval for Its First mRNA Influenza Vaccine—Commercial Prospects Still Await Validation

You may also like

Crypto prices